Anti-CD47 monoclonal antibody (immune checkpoint inhibitor) that blocks the CD47–SIRPα 'don’t‑eat‑me' signal to enhance macrophage-mediated phagocytosis of malignant myeloid cells.
Anti-CD47 monoclonal antibody that blocks the CD47–SIRPα checkpoint, removing the 'don’t-eat-me' signal and enhancing macrophage-mediated phagocytosis of malignant myeloid cells.
YES
INDIRECT
Blocking the CD47–SIRPα checkpoint removes the don’t-eat-me signal, enabling macrophage FcγR-mediated antibody-dependent cellular phagocytosis of CD47-positive cells.
A HER2-targeted antibody–drug conjugate linking the anti-HER2 antibody disitamab to the microtubule inhibitor monomethyl auristatin E (MMAE) via a cleavable linker; upon HER2 binding and internalization, MMAE is released to disrupt microtubules, causing G2/M arrest and apoptosis with a potential bystander effect.
HER2-targeted antibody–drug conjugate linking disitamab to the microtubule inhibitor MMAE via a cleavable linker; upon HER2 binding and internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing microtubule disruption, G2/M arrest, and apoptosis, with a potential bystander effect.
YES
DIRECT
ADC binds HER2 on target cells, is internalized, and releases MMAE, which inhibits tubulin polymerization causing microtubule disruption, G2/M arrest, and apoptosis (with potential bystander effect).
Autologous T cells genetically modified to express a chimeric antigen receptor targeting CD5; CAR engagement induces MHC-independent T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity against CD5+ malignant T cells, with potential on-target effects on normal CD5+ T cells.
Autologous T cells are engineered to express a chimeric antigen receptor targeting CD5. CAR engagement on CD5+ cells triggers MHC-independent T-cell activation and expansion, leading to cytokine release and perforin/granzyme-mediated cytotoxicity against CD5-expressing malignant T cells, with potential on-target effects on normal CD5+ T cells.
YES
DIRECT
CAR T cells bind CD5 on target cells, forming an immune synapse and inducing perforin/granzyme-mediated cytolysis (and death receptor pathways), killing CD5+ cells.
Chimeric IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC/CDC and apoptosis.
Chimeric IgG1 anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive cells via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.
YES
DIRECT
Anti-CD20 IgG1 binds CD20 on B cells and triggers Fc-mediated ADCC by effector cells, activates complement (CDC), and can induce apoptosis upon crosslinking.
A lyophilized peptide derived from human telomerase reverse transcriptase (hTERT) used as a therapeutic peptide vaccine; processed by antigen-presenting cells and presented via MHC to activate hTERT‑specific CD4+/CD8+ T‑cell responses, enabling immune recognition of telomerase‑expressing cells; administered subcutaneously.
A synthetic peptide derived from human telomerase reverse transcriptase (hTERT) that is taken up by antigen-presenting cells and presented on MHC class I and II to activate hTERT-specific CD8+ and CD4+ T cells, enabling immune recognition and killing of telomerase-expressing cells.
YES
INDIRECT
Peptide vaccine is taken up by APCs and presented on MHC I/II to prime hTERT-specific CD8+ (and CD4+) T cells; CTLs then recognize hTERT peptides on MHC I of telomerase-expressing cells and kill them via perforin/granzyme-mediated apoptosis.